Best Supplements for Heart Health in 2026: Evidence-Based Cardiovascular Support

Disclaimer: This guide is for informational purposes only and does not constitute medical advice. Cardiovascular disease is a serious medical condition requiring professional care. Supplements are not a substitute for prescribed medications, lifestyle modifications, or medical procedures. If you have diagnosed heart disease, heart failure, are taking anticoagulants, or have had a cardiac event, consult your cardiologist before starting any supplement regimen. Some supplements can interact with heart medications.

What Supplements Can (and Cannot) Do for Heart Health

Cardiovascular disease remains the leading cause of death in the United States, responsible for ~697,000 deaths annually. The most powerful interventions are lifestyle-based (diet quality, physical activity, smoking cessation, weight management) and medication-based (statins, antihypertensives, anticoagulants). Within this framework, certain supplements have strong evidence for supporting cardiovascular health — primarily through lipid modification, blood pressure reduction, and anti-inflammatory effects. It is critical to understand the evidence hierarchy: population associations, mechanistic studies, and short-term biomarker trials are much weaker evidence than large cardiovascular outcome RCTs. Below, we prioritize supplements with actual outcome data where available.

Supplements With Strong Cardiovascular Evidence

Omega-3 Fatty Acids (EPA/DHA) — The Best-Supported Supplement

Marine omega-3s (EPA and DHA) are the most evidence-backed supplements for cardiovascular health. At prescription doses, EPA alone (4g/day as icosapentaenoic acid, marketed as Vascepa/Lovaza) reduces major cardiovascular events. The landmark REDUCE-IT trial (8,179 patients, 5 years) found high-dose EPA reduced cardiovascular events by 25% vs. placebo in patients with elevated triglycerides on statin therapy (Bhatt et al., 2019). At supplement doses (1-3g/day): consistent reductions in triglycerides (20-50% at 3-4g/day), modest blood pressure reduction (-4/-3 mmHg), anti-inflammatory effects, and reduced platelet aggregation. A 2021 Cochrane review of 86 RCTs found omega-3 supplementation reduced: triglycerides (strong evidence), cardiovascular mortality (moderate evidence), and non-fatal myocardial infarction (modest evidence). Dose: 1-3g combined EPA+DHA for general cardiovascular support; higher doses require medical supervision. See our omega-3 supplements guide.

Magnesium — Blood Pressure and Cardiac Rhythm

Magnesium is involved in over 300 enzymatic reactions, including those regulating vascular tone, cardiac electrical conduction, and smooth muscle relaxation. Low magnesium status is independently associated with hypertension, arrhythmias, and increased cardiovascular risk in epidemiological studies. A 2016 meta-analysis of 34 RCTs found magnesium supplementation reduced systolic blood pressure by 2-4 mmHg and diastolic blood pressure by 1.5-3 mmHg in adults (Zhang et al., 2016). Effects are most pronounced in those with hypertension, diabetes, or magnesium deficiency. The cardiovascular risk reduction from blood pressure lowering alone is clinically meaningful. Dose: 200-420mg elemental magnesium/day in a bioavailable form (glycinate, malate). See our magnesium guide.

CoQ10 — Statin-Related Muscle Support and Heart Failure

Coenzyme Q10 is a fat-soluble antioxidant essential for mitochondrial energy production, concentrated in the heart. Statins deplete CoQ10 by inhibiting the same pathway that produces both cholesterol and CoQ10. Two main evidence areas: (1) Statin-associated myopathy: CoQ10 (100-300mg/day) is widely used to reduce muscle pain from statins; meta-analyses show mixed results (some show benefit, Cochrane review was inconclusive) — but CoQ10 is safe and worth trying in statin users with muscle symptoms; (2) Heart failure: the Q-SYMBIO trial (420 patients, 2 years) found CoQ10 (300mg/day) significantly reduced major adverse cardiovascular events and all-cause mortality in Class III-IV heart failure patients vs. placebo (Mortensen et al., 2014). This is one of the only supplement trials showing mortality benefit. Dose: 100-300mg/day ubiquinol (more bioavailable) or ubiquinone form with a fat-containing meal.

Berberine — Lipids and Blood Sugar

Berberine is an alkaloid extracted from several plants (barberry, Oregon grape, goldenseal) with remarkable cardiometabolic effects. A 2015 meta-analysis of 27 RCTs found berberine significantly reduced total cholesterol (-18mg/dL), LDL (-14mg/dL), triglycerides (-20mg/dL), and fasting blood glucose (-20mg/dL) vs. placebo (Dong et al., 2015). The lipid-lowering mechanism is distinct from statins (PCSK9 and AMPK pathways), making it complementary. Effects on blood sugar are mediated by AMPK activation — the same pathway targeted by metformin. Berberine interacts with several medications (particularly those metabolized by CYP enzymes); consult your physician if taking any prescription drugs. Dose: 500mg two to three times daily with meals. See our berberine guide.

Supplements With Moderate Evidence

Garlic Extract

Garlic has been used medicinally for millennia and has a reasonable body of evidence for cardiovascular benefit. A 2016 meta-analysis of 20 RCTs found garlic preparations significantly reduced systolic blood pressure (-4.6 mmHg) and diastolic blood pressure (-2.4 mmHg) in hypertensive patients (Ried et al., 2016). Evidence also suggests modest LDL reduction (-10mg/dL) and antiplatelet effects. Aged garlic extract (Kyolic) appears most consistent in studies. Dose: standardized to 5,000-12,000mcg allicin potential (about 600-1,200mg) daily. Note: antiplatelet effects mean garlic should be discontinued before surgery and used cautiously with anticoagulants.

Vitamin K2 (MK-7) — Arterial Calcification

Vitamin K2 (particularly MK-7 form) activates matrix Gla protein (MGP), a calcification inhibitor in arterial walls. Low K2 status is associated with higher coronary artery calcification scores in epidemiological studies. The Rotterdam Heart Study found higher dietary K2 intake associated with 57% lower cardiovascular mortality and 52% lower aortic calcification over 10 years (Geleijnse et al., 2004). RCT evidence is emerging but less definitive than observational data. Important for people supplementing calcium — vitamin K2 directs calcium to bone rather than arterial walls. Dose: 90-200mcg MK-7 daily. See our vitamin K2 supplement guide.

Supplements With Limited or Questionable Evidence

• Red yeast rice: Contains naturally occurring lovastatin (a statin) — can meaningfully lower LDL but with the same risks as pharmaceutical statins. Not recommended without medical supervision; FDA has banned high-potency versions as unapproved drugs in the US.
• Resveratrol: Mechanistically promising (SIRT1 activation, anti-inflammatory) but human outcome trials have been disappointing. Observational benefits seen in wine drinkers are likely confounded. The dose in wine is trivial compared to supplement doses. No cardiovascular outcome trial benefit demonstrated.
• Nattokinase: A fibrinolytic enzyme from natto; pilot studies show anticoagulant effects. Promising but limited by small trials and no outcome data. Significant bleeding risk if combined with anticoagulants.